Cure My Disease

Don't miss your cure!

 Log in / Sign up

Genetic matchmaking for antidepressants: a global trial puts personalization to the test

NCT ID NCT07796295

Disease control Sponsor: University of Oxford Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 01, 2026 · Last updated Sep 02, 2026 · Updated 1 time

Summary

This trial tests a web-based tool called PRADA that uses a person's genetics, symptoms, and preferences to help choose an antidepressant. Researchers will compare it to an older tool in adults with major depression across Ethiopia, Pakistan, and the UK. The goal is to see if the new tool helps people stay on their medication longer and improves their symptoms over 12 months.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
A web-based decision support tool that combines clinical, demographic, and genetic information to help patients and clinicians choose an antidepressant.
What this could lead to
If it works, this could point toward a more personalized way to prescribe antidepressants, helping more people stay on treatment and feel better.
What could go wrong
The trial is large but still experimental. The tool may not improve outcomes over the existing PETRUSHKA tool, and genetic testing may not add enough benefit in diverse settings.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 2,142 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Oct 2026

An estimate. Start dates often move.

Expected to finish

Oct 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 74 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion criteria: 1. Aged 18-74 years inclusive; 2. Willing and able to give informed consent for participation in the trial; 3. Clinical primary diagnosis of major depressive episode, for which an antidepressant is clinically indicated; 4. PHQ-9 score of at least 10; 5. Willing and able to start antidepressant treatment as monotherapy; 6. Able to understand and answer self-administered questionnaires in their local language. Exclusion Criteria 1. Taken an antidepressant in the preceding 4 weeks at a therapeutic dose; 2. Current or historical diagnosis (lifetime) of ADHD, bipolar disorder, dementia, mania/hypomania, psychosis/schizophrenia 3. Current or historical diagnosis (within 10 years) of any eating disorders, PTSD, OCD or alcohol/substance use disorder 4. Treatment Resistant Depression (i.e., having tried 2 or more antidepressants for the same depressive episode at adequate dose and time); 5. Known diagnosis of arrhythmias (including Q-T prolongation, heart block), recent myocardial infarction (within 5 years), difficult-to-treat epilepsy, acute porphyrias; 6. Requires urgent mental care or admission (including suicidal intent/plans); 7. Concurrently enrolled in another investigational medicinal product (IMP) trial that, in the opinion of the investigator, is likely to interfere with the PRADA trial or an interventional trial about depression; 8. Pregnant, planning pregnancy or lactating (self-reported); 9. Unable to give blood sample for genetic analysis.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Major depressive disorder (MDD) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Depression major depressive disorder Psychological Well-Being

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Major depressive disorder (MDD)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    3 sites in 3 countries. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Amanuel Mental Specialized Hospital

    Addis Ababa, Ethiopia

  • NIHR Clinical Research Facility Oxford Health

    Oxford, Oxfordshire, OX3 7JX, United Kingdom

  • Pakistan Institute of Living and Learning (PILL)

    Karachi, Pakistan

More trials for these conditions

Other studies related to the condition(s) this trial covers.